1. Search Result
Search Result
Isoforms Recommended: PDE4
Results for "

PDE4C

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-119190

    Phosphodiesterase (PDE) Neurological Disease
    PF-06445974, a promising positron emission tomography (PET) lead, has exquisite potency at PDE4B with an IC50 <1 nM. The IC50 values are 36, 4.7 and 17 nM for PDE4D, PDE4A and PDE4C, respectively. PF-06445974 has good selectivity over PDE4D, excellent brain permeability, and a high level of specific binding in the "cold tracer" study .
    PF-06445974
  • HY-100246

    PD-189659

    Phosphodiesterase (PDE) Inflammation/Immunology
    CI-1044 is an orally active PDE4 inhibitor with IC50s of 0.29, 0.08, 0.56, 0.09 μM for PDE4A5, PDE4B2, PDE4C2 and PDE4D3, respectively.
    CI-1044
  • HY-103050
    ML-030
    1 Publications Verification

    Phosphodiesterase (PDE) Inflammation/Immunology
    ML-030 is a potent PDE4 inhibitor, with IC50 of 6.7 nM, 12.9 nM, 48.2 nM, 37.2 nM, 452 nM and 49.2 nM for PDE4A, PDE4A1, PDE4B1, PDE4B2, PDE4C1,and PDE4D2, respectively.
    ML-030
  • HY-128358
    MR-L2
    1 Publications Verification

    Phosphodiesterase (PDE) Neurological Disease
    MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 μM .
    MR-L2
  • HY-RS10224

    Small Interfering RNA (siRNA) Others

    PDE4C Human Pre-designed siRNA Set A contains three designed siRNAs for PDE4C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PDE4C Human Pre-designed siRNA Set A
    PDE4C Human Pre-designed siRNA Set A
  • HY-131707

    Phosphodiesterase (PDE) Inflammation/Immunology
    LEO 39652 is a dual-soft PDE4 inhibitor with IC50s of 1.2 nM, 1.2 nM, 3.0 nM and 3.8 nM for PDE4A, PDE4B, PDE4C and PDE4D, respectively. LEO 39652 also inhibits TNF-α with an IC50 value of 6.0 nM. LEO 39652 is used for topical research of Atopic dermatitis (AD) .
    LEO 39652
  • HY-179504

    Phosphodiesterase (PDE) TNF Receptor Inflammation/Immunology
    PDE4B-IN-6 (compound 4i) is a potent and selective PDE4B inhibitor with an IC50 of 7.42 nM. PDE4B-IN-6 shows ~195- and ~169-fold selectivity for PDE4B over PDE4A (IC50 = 1540 nM) and PDE4C (IC50 = 1260 nM), respectively. PDE4B-IN-6 increases cAMP level and suppresses TNF-α expression. PDE4B-IN-6 shows favorable antioxidant profiles and low cytotoxicity. PDE4B-IN-6 can be used for chronic obstructive pulmonary disease (COPD) research .
    PDE4B-IN-6
  • HY-114052

    Phosphodiesterase (PDE) Inflammation/Immunology
    NVP-ABE171 is an efficient, long-lasting and orally active PDE4 inhibitor with IC50 values for PDE4D, PDE4B, PDE4A and PDE4C of 1.5, 34, 602 and 1230 nM respectively. NVP-ABE171 enhances the cAMP accumulation induced by isoproterenol, inhibits the oxidative burst of eosinophils and the release of inflammatory cytokines from T cells and monocytes. NVP-ABE171 exhibits potent anti-inflammatory activity in animal models of asthma and pulmonary inflammation. NVP-ABE171 can be used for research on asthma and chronic obstructive pulmonary disease .
    NVP-ABE171
  • HY-201403

    Phosphodiesterase (PDE) TNF Receptor Inflammation/Immunology
    LY2775240 is an orally active phosphodiesterase 4 (PDE4) inhibitor with potent inhibitory activity against PDE4A (IC50 = 0.09 nM), PDE4B (IC50 = 0.09 nM) and PDE4D (IC50 = 0.14 nM), and exhibits an IC50 of 2.4 nM against PDE4C. LY2775240 is a highly selective agent that reduces TNFα production upon immune activation. LY2775240 decreases TNFα production in rodent and rhesus monkey models. LY2775240 can be used in the research of psoriasis .
    LY2775240
  • HY-119799

    Phosphodiesterase (PDE) Inflammation/Immunology
    UK-500001 is an orally active inhibitor for phosphodiesterase 4 (PDE4), which inhibits PDE4D3 (IC50 is 0.28 nM), PDE4B2 (IC50 is 22.8 nM), PDE4A4 (IC50 is 26.1 nM) and PDE4C2 (IC50 is 271 nM). UK-500001 exhibits anti-inflammatory efficacy and inhibits TNF-α and IFN-γ release in human and rodent macrophagic cell lines in nanomolar levels. UK-500001 ameliorates chronic obstructive pulmonary disease (COPD) and asthma .
    UK-500001
  • HY-103050R

    Reference Standards Phosphodiesterase (PDE) Inflammation/Immunology
    ML-030 (Standard) is the analytical standard of ML-030 (HY-103050). This product is intended for research and analytical applications. ML-030 is a potent PDE4 inhibitor, with IC50 of 6.7 nM, 12.9 nM, 48.2 nM, 37.2 nM, 452 nM and 49.2 nM for PDE4A, PDE4A1, PDE4B1, PDE4B2, PDE4C1,and PDE4D2, respectively.
    ML-030 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: